Biocryst Pharmaceuticals (BCRX) Research & Development (2010 - 2026)

Biocryst Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $60.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 61.84% year-over-year to $60.3 million; the trailing twelve-month figure through Mar 2026 stood at $189.2 million (up 14.36% YoY), and the FY2025 full-year result was $166.1 million, down 4.87% from the prior year.
• Research & Development for Q1 2026 stood at $60.3 million, up from $40.9 million in the prior quarter.
• The five-year high for Research & Development was $73.2 million in Q4 2022, with the low at $37.3 million in Q1 2025.
• Historically, Research & Development has averaged $51.2 million across 5 years, with a median of $48.4 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development dropped 29.42% — and 2026, when it surged 61.84%.
• Biocryst Pharmaceuticals' Research & Development stood at $73.2 million in 2022, then slipped by 4.31% to $70.1 million in 2023, then fell by 29.42% to $49.4 million in 2024, then decreased by 17.34% to $40.9 million in 2025, then surged by 47.6% to $60.3 million in 2026.
• The last three Research & Development figures came in at $60.3 million (Q1 2026), $40.9 million (Q4 2025), and $44.6 million (Q3 2025), per Business Quant data.